Tick-borne encephalitis
diseaseOn this page
Also known as TBETick-borne viral encephalitis
Summary
Tick-borne encephalitis (MONDO:0017572) is a disease and 27 clinical trials. Top therapeutic interventions include sodium chloride. A subtype of viral encephalitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Worldwide)
- Phenotypes (HPO): 63
- Clinical trials: 27
Clinical features
Signs & symptoms
Clinical features (HPO)
63 HPO clinical features (Orphanet curated; top 50 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0012229 | CSF pleocytosis | Very frequent (80-99%) |
| HP:0001882 | Leukopenia | Frequent (30-79%) |
| HP:0002018 | Nausea | Frequent (30-79%) |
| HP:0002039 | Anorexia | Frequent (30-79%) |
| HP:0002315 | Headache | Frequent (30-79%) |
| HP:0002829 | Arthralgia | Frequent (30-79%) |
| HP:0003326 | Myalgia | Frequent (30-79%) |
| HP:0011112 | Abnormality of serum cytokine level | Frequent (30-79%) |
| HP:0012378 | Fatigue | Frequent (30-79%) |
| HP:0020071 | Viremia | Frequent (30-79%) |
| HP:0000360 | Tinnitus | Occasional (5-29%) |
| HP:0000365 | Hearing impairment | Occasional (5-29%) |
| HP:0000505 | Visual impairment | Occasional (5-29%) |
| HP:0000602 | Ophthalmoplegia | Occasional (5-29%) |
| HP:0000613 | Photophobia | Occasional (5-29%) |
| HP:0000708 | Atypical behavior | Occasional (5-29%) |
| HP:0000716 | Depression | Occasional (5-29%) |
| HP:0000751 | Personality changes | Occasional (5-29%) |
| HP:0001262 | Excessive daytime somnolence | Occasional (5-29%) |
| HP:0001287 | Meningitis | Occasional (5-29%) |
| HP:0001291 | Abnormal cranial nerve morphology | Occasional (5-29%) |
| HP:0001308 | Tongue fasciculations | Occasional (5-29%) |
| HP:0001337 | Tremor | Occasional (5-29%) |
| HP:0001873 | Thrombocytopenia | Occasional (5-29%) |
| HP:0001974 | Leukocytosis | Occasional (5-29%) |
| HP:0002013 | Vomiting | Occasional (5-29%) |
| HP:0002015 | Dysphagia | Occasional (5-29%) |
| HP:0002311 | Incoordination | Occasional (5-29%) |
| HP:0002321 | Vertigo | Occasional (5-29%) |
| HP:0002360 | Sleep abnormality | Occasional (5-29%) |
| HP:0002487 | Hyperkinetic movements | Occasional (5-29%) |
| HP:0003202 | Skeletal muscle atrophy | Occasional (5-29%) |
| HP:0003237 | Increased circulating IgG level | Occasional (5-29%) |
| HP:0003418 | Back pain | Occasional (5-29%) |
| HP:0003470 | Paralysis | Occasional (5-29%) |
| HP:0003474 | Somatic sensory dysfunction | Occasional (5-29%) |
| HP:0003496 | Increased circulating IgM level | Occasional (5-29%) |
| HP:0003565 | Elevated erythrocyte sedimentation rate | Occasional (5-29%) |
| HP:0004372 | Reduced consciousness/confusion | Occasional (5-29%) |
| HP:0009763 | Limb pain | Occasional (5-29%) |
| HP:0011098 | Speech apraxia | Occasional (5-29%) |
| HP:0011227 | Elevated circulating C-reactive protein concentration | Occasional (5-29%) |
| HP:0011392 | Abnormality of the vestibular nerve | Occasional (5-29%) |
| HP:0011450 | Unusual CNS infection | Occasional (5-29%) |
| HP:0012332 | Abnormal autonomic nervous system physiology | Occasional (5-29%) |
| HP:0025258 | Stiff neck | Occasional (5-29%) |
| HP:0031987 | Diminished ability to concentrate | Occasional (5-29%) |
| HP:0032044 | Decreased vigilance | Occasional (5-29%) |
| HP:0100543 | Cognitive impairment | Occasional (5-29%) |
| HP:3000047 | Abnormal glossopharyngeal nerve morphology | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | tick-borne encephalitis |
| Mondo ID | MONDO:0017572 |
| EFO | EFO:1001309 |
| MeSH | D004675 |
| Orphanet | 297 |
| DOID | DOID:0050175 |
| ICD-10-CM | A84 |
| ICD-11 | 835129952 |
| NCIT | C34579 |
| UMLS | C0014061 |
| MedGen | 4034 |
| GARD | 0005216 |
| MedDRA | 10043848 |
| Is cancer (heuristic) | no |
Also known as: TBE · Tick-borne viral encephalitis
Disease family
This is a subtype of viral encephalitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › encephalomyelitis › encephalitis › infectious encephalitis › viral encephalitis › tick-borne encephalitis
Related subtypes (11): Powassan encephalitis, acute necrotizing encephalitis, acute hemorrhagic encephalitis, Colorado tick fever, eastern equine encephalitis, subacute sclerosing panencephalitis, herpes simplex encephalitis, encephalitis lethargica, mosquito-borne viral encephalitis, HHV-6 encephalitis, borna virus encephalitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 27.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE4 | 8 |
| Not specified | 8 |
| PHASE2 | 5 |
| PHASE3 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00161785 | PHASE4 | COMPLETED | Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years |
| NCT00804219 | PHASE4 | COMPLETED | Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination |
| NCT01106482 | PHASE4 | COMPLETED | An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE |
| NCT01562444 | PHASE4 | COMPLETED | Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules |
| NCT01582698 | PHASE4 | COMPLETED | TBE Seropersistence up to 10 Years After First Booster in Adults |
| NCT01710189 | PHASE4 | COMPLETED | Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac |
| NCT04017052 | PHASE4 | UNKNOWN | Application of a TBE-Vaccine in Obese Persons |
| NCT04573205 | PHASE4 | UNKNOWN | Primary TBE Vaccination for the Elderly |
| NCT07584525 | PHASE3 | RECRUITING | Dexamethasone in Tick-borne Encephalitis |
| NCT00161863 | PHASE3 | COMPLETED | Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years |
| NCT01361776 | PHASE2/PHASE3 | COMPLETED | Humoral Response to Tick-borne Encephalitis Vaccine in Elderly |
| NCT02318069 | PHASE2/PHASE3 | COMPLETED | New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly |
| NCT04648241 | PHASE3 | COMPLETED | Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older |
| NCT00161772 | PHASE2 | COMPLETED | Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years. |
| NCT00161798 | PHASE2 | COMPLETED | Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years. |
| NCT00890422 | PHASE2 | UNKNOWN | Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine |
| NCT01031537 | PHASE2 | TERMINATED | Vaccine Study for Tick-Borne Encephalitis Virus (TBEV) |
| NCT01991067 | PHASE2 | COMPLETED | Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients |
| NCT00118924 | PHASE1 | COMPLETED | Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults |
| NCT03956446 | Not specified | RECRUITING | Tick-borne Encephalitis and Borrelial Antibodies in Serum |
| NCT06859619 | Not specified | NOT_YET_RECRUITING | Serological Measurement of Montpellier Professionals’ Contacts with Infectious Agents Responsible for Animal-borne Diseases |
| NCT07274046 | Not specified | RECRUITING | Burden of Tick-borne Encephalitis and Cost-effectiveness of Vaccination in the Czech Republic |
| NCT07358910 | Not specified | RECRUITING | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective |
| NCT02463942 | Not specified | UNKNOWN | Tick-borne Encephalitis and Positive Borrelial Antibodies |
| NCT03958058 | Not specified | COMPLETED | Tick-borne Encephalitis and Possible Borrelial Serology |
| NCT05607394 | Not specified | UNKNOWN | Prevalence of Tick-borne Encephalitis in the Pediatric Population Treated at the HUS and Characterization of Confirmed Pediatric Cases |
| NCT05941546 | Not specified | COMPLETED | Tick-borne Encephalitis Virus Research in Limousin |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| SODIUM CHLORIDE | 4 | 1 |
Related Atlas pages
- Drugs: Sodium Chloride